Your session is about to expire
← Back to Search
Antiplatelet
Clopidogrel + Aspirin for Stroke (CoPrime Trial)
Phase 2
Waitlist Available
Led By Brian Buck
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must be over 18 years of age at the time of randomization
Premorbid mRS less than or equal to 2
Must not have
Post-reperfusion CT scan ASPECT score less than 8
Any known disorder associated with a significantly increased risk of bleeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to study the use of dual antiplatelet treatment in preventing recurrent strokes in patients who have had an ischemic stroke. Ischemic strokes are caused by a blocked blood vessel in the
Who is the study for?
This trial is for patients who've had an ischemic stroke and have been treated with thrombectomy or IV thrombolysis. They must be at low risk of bleeding to participate, as determined by screening after their initial treatment.
What is being tested?
The CoPrime study tests if taking aspirin plus clopidogrel (dual antiplatelet treatment) is safer and more effective than just aspirin in preventing another stroke within the first 21 days post-treatment.
What are the potential side effects?
Potential side effects include increased risk of bleeding due to the blood-thinning properties of both aspirin and clopidogrel when used alone or together.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am over 18 years old.
Select...
I was mostly independent in daily activities before my current illness.
Select...
I had a stroke treated with clot-busting drugs or a procedure to remove the clot.
Select...
I've had a CT scan after reperfusion therapy showing no bleeding or contrast leakage.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My brain scan score after treatment is below 8.
Select...
I have a condition that greatly increases my risk of bleeding.
Select...
I am scheduled for surgery soon, including procedures on my arteries, without specific blood thinning medication plans.
Select...
I have had bleeding in my brain.
Select...
I need blood thinners for reasons other than preventing blood clots in my legs.
Select...
I do not have an active cancer being treated and my life expectancy is more than 90 days.
Select...
My stroke was caused by an infection in the heart, a tear in an artery, or inflammation of blood vessels.
Select...
I need medication to prevent blood clots.
Select...
I have a brain tumor, arteriovenous malformation, or aneurysm.
Select...
I have a bleeding disorder with low platelets and high INR.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility
Safety
Secondary study objectives
Early Neurological Deterioration
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Dual Antiplatelet GroupExperimental Treatment1 Intervention
Group II: Aspirin GroupActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aspirin + clopidogrel
2005
Completed Phase 4
~60
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
942 Previous Clinical Trials
434,209 Total Patients Enrolled
26 Trials studying Stroke
2,731 Patients Enrolled for Stroke
Brian BuckPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Stroke
20 Patients Enrolled for Stroke
Mahesh KatePrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
51 Total Patients Enrolled
1 Trials studying Stroke
51 Patients Enrolled for Stroke